In the latest session, AVITA Medical Inc (NASDAQ: RCEL) closed at $10.35 down -28.32% from its previous closing price of $14.44. In other words, the price has decreased by -$4.09 from its previous closing price. On the day, 2052064 shares were traded.
Ratios:
For a deeper understanding of AVITA Medical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.46 and its Current Ratio is at 7.88. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.85.
On June 27, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $23.
On March 02, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on March 02, 2021, with a $27 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 28 ’24 when O’Toole David D bought 1,250 shares for $17.39 per share. The transaction valued at 21,738 led to the insider holds 18,734 shares of the business.
CORBETT JAMES sold 1,445 shares of RCEL for $19,204 on Dec 26 ’23. The CEO now owns 11,580 shares after completing the transaction at $13.29 per share. On Dec 13 ’23, another insider, COOK JEREMY CURNOCK, who serves as the Director of the company, sold 2,518 shares for $12.27 each. As a result, the insider received 30,896 and left with 20,596 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCEL now has a Market Capitalization of 266.06M and an Enterprise Value of 219.42M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.13 while its Price-to-Book (P/B) ratio in mrq is 5.42. Its current Enterprise Value per Revenue stands at 4.38 whereas that against EBITDA is -6.54.
Stock Price History:
Over the past 52 weeks, RCEL has reached a high of $21.70, while it has fallen to a 52-week low of $9.16. The 50-Day Moving Average of the stock is 16.55, while the 200-Day Moving Average is calculated to be 14.87.
Shares Statistics:
For the past three months, RCEL has traded an average of 168.20K shares per day and 329.68k over the past ten days. A total of 25.68M shares are outstanding, with a floating share count of 23.76M. Insiders hold about 4.35% of the company’s shares, while institutions hold 28.82% stake in the company. Shares short for RCEL as of Mar 15, 2024 were 590.73k with a Short Ratio of 4.32, compared to 501.87k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.30% and a Short% of Float of 2.31%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.26 and a low estimate of -$0.61, while EPS last year was -$0.37. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.23 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$0.19 and -$1.69 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.17, with 6 analysts recommending between -$0.01 and -$0.29.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $14.44M this quarter.It ranges from a high estimate of $15.8M to a low estimate of $11.08M. As of the current estimate, AVITA Medical Inc’s year-ago sales were $10.35M, an estimated increase of 39.50% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $17.81M, an increase of 51.50% over than the figure of $39.50% in the same quarter last year. There is a high estimate of $19.7M for the next quarter, whereas the lowest estimate is $15.87M.
A total of 8 analysts have provided revenue estimates for RCEL’s current fiscal year. The highest revenue estimate was $82.94M, while the lowest revenue estimate was $75.01M, resulting in an average revenue estimate of $79.33M. In the same quarter a year ago, actual revenue was $50.14M, up 58.20% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $110.65M in the next fiscal year. The high estimate is $122.9M and the low estimate is $95.11M. The average revenue growth estimate for next year is up 39.50% from the average revenue estimate for this year.
